WCK 771

Drug Profile

WCK 771

Alternative Names: WCK 771A; WCK771

Latest Information Update: 03 Aug 2016

Price : $50

At a glance

  • Originator Wockhardt
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; Membrane protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Methicillin-resistant Staphylococcus aureus infections
  • No development reported Skin and soft tissue infections

Most Recent Events

  • 09 Apr 2016 Pharmacokinetics and adverse event data from a clinical trial in volunteers presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2016)
  • 07 Sep 2015 No recent reports on development identified - Phase-II for Methicillin-resistant Staphylococcus aureus infections and Skin and soft tissue infections in India (IV)
  • 31 Aug 2014 Phase I development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top